2003, Clinical Development, Licensing and RNA

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2003

Clinical Development

Licensing

RNA

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

MARCH 8, 2021

We continue to make progress in our Phase 2/3 clinical programs evaluating molnupiravir in both outpatient and hospital settings and plan to provide updates when appropriate,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Trials

Trials Virus RNA Research Laboratories

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. This is reflected by our recent share price performance outperforming the index in the past year.”

Drugs

Drugs Science Therapies Targeted Protein Degradation

Drug Discovery Digest

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

Where is the drug discovery expertise happening in the UK?

Stay Connected